+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic value of human mature adrenomedullin in patients with acute myocardial infarction



Prognostic value of human mature adrenomedullin in patients with acute myocardial infarction



Journal of Cardiovascular Medicine 18(1): 42-50



Adrenomedullin (ADM) correlates with adverse cardiovascular outcomes in patients with acute myocardial infarction (AMI) and in patients with heart failure. Measurement of human mature ADM (mADM) has been difficult, and recent studies have used its surrogate - the mid-regional pro-ADM (MRproADM). Our objective was to determine whether mADM measured by a novel sandwich immunoassay, using the anti-C-terminal and an anti-mid-regional monoclonal antibody, was prognostic of 30-day, 90-day, 1-year, and 2-year major adverse cardiovascular events (MACEs) in 1111 consecutive patients who have suffered an AMI. We also compared it with the effect of MRproADM in the same patient population. A total of 311 (27.0%) patients experienced the primary endpoint at 2 years follow-up. The median (inter-quartile range) of mADM was significantly higher in patients who experienced a 2-year MACE [60.90 (44.00-86.97)] pg/ml, compared to event-free survivors [49.59 (36.20-68.15)] pg/ml (P < 0.001). mADM, taken as 1 SD of the continuous variable, was predictive of MACEs in multivariate analysis, with hazard ratios [95% confidence intervals (CIs)] at 90 days [1.28 (1.01-1.62)], 1 year [1.31 (1.08-1.59)], and 2 years [1.42 (1.07-1.64)]. It was also independently predictive of death at 1-year [1.52 (1.12-2.05)] and 2-year [1.42 (1.07-1.89)] follow-up. mADM was a better predictor of these outcomes than MRproADM, apart from death at 90 days, and combined death and heart failure hospitalization at 1 and 2 years, respectively. Human mADM can be reliably measured and predicts MACE events at medium-term follow-up, and confirms the paradigm of risk stratification using MRproADM - a surrogate for the active hormone. The relationship between mADM and MACE appears to be a continuum.

(PDF emailed within 0-6 h: $19.90)

Accession: 058637796

Download citation: RISBibTeXText

PMID: 26766169

DOI: 10.2459/JCM.0000000000000299


Related references

Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. Journal of the American College of Cardiology 49(14): 1525-1532, 2007

Mature-type adrenomedullin in coronary circulation immediately after reperfusion in patients with anterior acute myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi 34(7): 613-615, 2006

Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction. Heart 97(11): 892-898, 2011

Up-regulated synthesis of mature-type adrenomedullin in coronary circulation immediately after reperfusion in patients with anterior acute myocardial infarction. Regulatory Peptides 129(1-3): 161-166, 2005

Long-term prognostic value of mid-regional pro-adrenomedullin and C-terminal pro-endothelin-1 in patients with acute myocardial infarction. Clinical Chemistry and Laboratory Medicine 46(2): 204-211, 2007

Prognostic value of mid-regional pro-adrenomedullin levels taken on admission and discharge in non-ST-elevation myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) II study. Journal of the American College of Cardiology 56(2): 125-133, 2010

Comparison of long-term prognostic value of N-terminal-proBNP and midregional-pro-adrenomedullin in patients with acute myocardial infarction. Clinical Laboratory 56(7-8): 303-309, 2010

Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial. American Heart Journal 160(4): 671-677, 2010

Plasma adrenomedullin as a prognostic determinant after acute myocardial infarction. Journal of the American College of Cardiology 31(2 SUPPL A): 14A, 1998

Prognostic significance of adrenomedullin in patients with heart failure and with myocardial infarction. American Journal of Cardiology 115(7): 986-991, 2015

Myocardial production of adrenomedullin in patients with reperfused anterior acute myocardial infarction. Circulation 106(19 Supplement): II-528, November 5, 2002

C-terminal pro-endothelin-1 offers additional prognostic information in patients after acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study. American Heart Journal 154(4): 736-742, 2007

Deleterious prognostic significance of low body mass index in patients with acute myocardial infarction One-year results from a nationwide French registry of acute myocardial infarction. Circulation 104(17 Supplement): II 698, October 23, 2001

Suboptimal use of evidence-based medical therapy in patients with acute myocardial infarction from the Korea Acute Myocardial Infarction Registry: prescription rate, predictors, and prognostic value. American Heart Journal 159(6): 1012-1019, 2010

Prognostic evaluation by clinical exercise test scores in patients treated with primary percutaneous coronary intervention or fibrinolysis for acute myocardial infarction (a Danish Trial in Acute Myocardial Infarction-2 Sub-Study). American Journal of Cardiology 100(7): 1074-1080, 2007